Karyopharm Therapeutics to present at two major healthcare investor conferences in May

Karyopharm Therapeutics, a pharmaceutical company specializing in novel cancer therapies, announced that its senior management will participate in two investor conferences on May 19, 2026: the H.C. Wainwright 4th Annual BioConnect and the RBC 2026 Global Healthcare Conference. Both events will feature fireside chats and will be webcast live on the company's website. This participation highlights Karyopharm's ongoing efforts to engage with investors and showcase its progress with its lead cancer drug, XPOVIO (selinexor), which is approved in multiple countries. Investors can access the presentations online and replay them after the events.